Systematic Evaluation of Bone Health Dynamics Associated With GLP-1 Receptor Agonists in Type 2 Diabetes Patients: Fracture Risk and Osteoporotic Complications
Moderator
Dawn Webster, MPAS, PA-C, Optum, Pittsburgh, PA, United States
Speakers
Arunima Sachdev, MA, Optum, Gurgaon, India; Ina Kukreja, Optum, New Delhi, India; Vikash K Verma, MBA, PharmD, Optum Lifesciences, Boston, MA, United States; Abhimanyu Roy, MBA; Abhinav Nayyar, Optum Life Sciences, Gurugram, India; Rahul Goyal; Louis Brooks Jr; Marissa Seligman
OBJECTIVES: The objective of this study is to investigate the impact of GLP-1 receptor agonists on bone health in patients and to evaluate the associated risk of fractures. This research aims to provide insights into the potential effects of GLP-1 drugs on skeletal health, identifying any correlations between drug use, changes in bone density, and the incidence of fractures, ultimately guiding safer therapeutic practices and patient management.
METHODS: We conducted a retrospective study using the Optum® Market Clarity Dataset, focusing on patients diagnosed with Type 2 Diabetes (T2D) aged 18 years or older between January 1, 2018, and December 31, 2022, identified using ICD-10 diagnosis codes (E11*). The population was divided into mutually exclusive groups of patients with GLP-1 (Cases) and patients without GLP-1 (Controls). To reduce the confounding effects of demographic factors and comorbidities, exact matching was performed on age, gender, region, and Charlson comorbidity score. Bone health was then assessed during 12-month pre- and post-index periods between the two groups through clinical notes using verbatim such as “fall”, “fracture” and diagnosis of osteoporotic complications.
RESULTS: The study included about 11.7 million patients with T2D diagnosis. The pre-matched analysis provided 1.9M patients with GLP1 and 9.7M patients without GLP1. The matched population depicts a significant difference between the two groups in terms of fracture risk and osteoporotic complications in the 12-month post-index period (p<0.05) with patients using GLP-1 showcasing preservation of bone health. Additional analysis will be performed to assess the strength of correlation using odds ratio and confidence interval.
CONCLUSIONS: This study concludes that GLP-1 was associated with a significant reduction in the risk of bone fractures, and preservation of bone health in T2D patients. This study also throws light on possible safer therapeutic practices and patient journey management for diabetes patients.
METHODS: We conducted a retrospective study using the Optum® Market Clarity Dataset, focusing on patients diagnosed with Type 2 Diabetes (T2D) aged 18 years or older between January 1, 2018, and December 31, 2022, identified using ICD-10 diagnosis codes (E11*). The population was divided into mutually exclusive groups of patients with GLP-1 (Cases) and patients without GLP-1 (Controls). To reduce the confounding effects of demographic factors and comorbidities, exact matching was performed on age, gender, region, and Charlson comorbidity score. Bone health was then assessed during 12-month pre- and post-index periods between the two groups through clinical notes using verbatim such as “fall”, “fracture” and diagnosis of osteoporotic complications.
RESULTS: The study included about 11.7 million patients with T2D diagnosis. The pre-matched analysis provided 1.9M patients with GLP1 and 9.7M patients without GLP1. The matched population depicts a significant difference between the two groups in terms of fracture risk and osteoporotic complications in the 12-month post-index period (p<0.05) with patients using GLP-1 showcasing preservation of bone health. Additional analysis will be performed to assess the strength of correlation using odds ratio and confidence interval.
CONCLUSIONS: This study concludes that GLP-1 was associated with a significant reduction in the risk of bone fractures, and preservation of bone health in T2D patients. This study also throws light on possible safer therapeutic practices and patient journey management for diabetes patients.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO4
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Clinician Reported Outcomes
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)